Astec LifeSciences has announced the approval of its audited financial results for the quarter and financial year ended 31st March 2026. The decision was made during a Board meeting held on 27th April 2026.
The Board of Directors, following the recommendation of the Audit Committee, approved the standalone and consolidated financial results in accordance with Indian Accounting Standards (IND AS). The results include the Cash Flow Statement and the Statement of Assets and Liabilities as of 31st March 2026.
Additionally, the Board noted the Statutory Auditors’ Reports on the financial results, which were presented with an unmodified opinion. This indicates that the auditors found the financial statements to be in compliance with the applicable accounting standards and free from material misstatements.
The Board also addressed matters related to the upcoming 32nd Annual General Meeting (AGM), which is scheduled for 31st July 2026. The book closure dates for the AGM are set from 26th July to 30th July 2026.
Furthermore, the Board approved a proposal to seek shareholder approval via postal ballot for several items, including the appointment of Mr. Vishal Sharma and Mr. Burjis N. Godrej as Non-Executive Directors, the appointment and remuneration of Mr. Arijit Mukherjee as an Executive Director, the appointment of Mr. Mathew Eipe as an Independent Director, and approval for entering into material related party transactions for the financial year 2026-27.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).